Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus WESTCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus WESTCORT.
COR-OTICIN vs WESTCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%)
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid